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Purpose. Radiation of extremity lesions, a key component of limb-sparing therapy, presents particular challenges, with significant
risks of toxicities. We sought to explore the efficacy of intraoperative radiation therapy (IORT) in the treatment of soft tissue sar-
comas of the extremities. Patients. Between 1995 and 2001, 17 patients received IORT for soft tissue sarcomas of the extremities.
Indications for IORT included recurrent tumors in a previously radiated field or tumors adjacent to critical structures. Results.
Gross total resections were achieved in all 17 patients. Two patients experienced locoregional relapses, six patients recurred at
metastatic sites, and one patient died without recurrence. Thirty-six month estimates for locoregional control, disease free sur-
vival, and overall survival were 86%, 50%, and 78%, respectively. IORT was extremely well tolerated, with no toxicities referable
to IORT. Conclusions. For patients with soft tissue sarcomas of the extremities, IORT used as a boost to EBRT provides excellent
local control, with limited acute toxicities.
Copyright © 2006 Quy N. H. Tran et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Soft-tissue sarcomas (STSs) are relatively uncommon tu-
mors, representing 1% of adult and 7%–15% of pediatric
malignancies. They are a relatively heterogeneous group of
cancers that occur anywhere in the body, with 60% arising in
the extremities. There are at least 30 distinct histologic sub-
types of sarcomas that are further defined by grade [1]. Such
diversity may present a clinical challenge, but for treatment
purposes, most soft-tissue sarcomas are grouped together.
Important prognostic factors, reflected in the newly revised
American Joint Committee on Cancer (AJCC) staging sys-
tem, include histologic grade, relationship to fascial planes,
and size of the primary tumor [2].
In the past, sarcomas arising in the extremities were fre-
quently treated with amputation, as limited resections re-
sulted in poor local control rates. In the past two decades,
limb-salvage approaches have drawn interest and attention,
particularly with the recent advent of multimodality therapy.
Treatment regimens that combine surgery, chemotherapy,
and radiation have allowed treating physicians to maintain
function without compromising disease control [3–10].
Limb-sparing therapy is therefore becoming the standard of
care [11, 12], with less than 10% of patients currently un-
dergoing amputation as primary therapy. With modern ap-
proaches, local control rates using limb-sparing techniques
exceed 75% for primary extremity lesions [11, 13].
Recently, intraoperative radiation therapy (IORT) has
been gaining favor. At our institution, IORT consists of a
single fraction of radiation, using electrons, administered at
the time of resection. Critical structures can be visualized
and manipulated to avoid dose-limiting toxicities to normal
structures, while a higher dose can be applied to residual tu-
mor volume and sites at high risk for microscopic disease.
Retrospective studies of various malignancies have suggested
that IORT may improve local control compared to standard
radiotherapy [14–18].
In conjunction with external beam radiation therapy
(EBRT), IORT contributes to higher total doses of radiation
to the tumor bed, while limiting long-term side effects. Thus,
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IORT allows for potentially higher local control rates while
reducing radiation toxicities [14–20]. Early clinical trials uti-
lizing IORT have reported favorable local control rates with
few patients experiencing IORT-related side effects [21, 22].
Radiation has a well-established role in the treatment of
sarcomas, and we sought to enhance local control without
increasing radiation-induced toxicities by utilizing IORT as a
boost. Specifically, in this study, we sought to determine the
rates of local control, disease-free survival (DFS), overall sur-
vival (OS), and acute toxicities in patients who had received
limb-sparing therapy with IORT for sarcomas of the extrem-
ities at the University of California, San Francisco (UCSF).
PATIENTS
In this retrospective study, we report on 17 patients with
soft-tissue extremity sarcomas who were treated with limb-
sparing therapy, including IORT, between 1995 and 2001.
Details of surgery, radiation, chemotherapy, as well as
imaging studies and pathological diagnoses were acquired.
Follow-up duration was calculated from the date of IORT
until the last known or documented visit or the date of death.
Patients were staged according to the AJCC staging system
for sarcomas that incorporates histologic grade, tumor size,
lymph node status, and metastases [2]. All patients in this
study had gross total resections (GTRs) with IORT at the
time of surgery.
Intraoperative radiation therapy boosts for extremity sar-
comas have been used at UCSF since 1995, but prior to 1997,
IORT was delivered in a suite in the Radiation Oncology De-
partment; patients were brought to the room at the time of
or within 2 days of surgery. Since 1997, patients have received
IORT at the time of primary resection within the operating
room, bymeans of a dedicatedmobile linear accelerator [23].
Electron beams were delivered through lucite or aluminum
cones 3–10 cm in interior diameter. Beam energies ranging
from 4MeV to 12MeV were used to limit the depth of the
absorbed dose to the areas at risk, while encompassing the
target volumes within the 90% isodose line. Themedian dose
was 12.5Gy (range 12–15Gy) delivered in a single fraction.
One to two separate IORT fields were used to cover the entire
target volume. The surgeon and radiation oncologist made
final decisions at the time of surgery regarding the areas at
risk for microscopic residual disease. The target volume was
the tumor bed as determined by preoperative imaging, op-
erative findings, and, when necessary, intraoperative frozen
sections. Shielding of normal tissues not at risk for disease
was accomplished by physical manipulation to exclude them
from the radiation field, or by lead sheets.
The indications for IORT included recurrent tumors
within a previously radiated field, or tumors where mar-
gin status was in question, due to close proximity of criti-
cal structures, such as nerves or vessels. Patients with tumors
close to critical structures were treated with IORT as a boost,
rather than preoperative radiation, because of the increased
wound complications seen with preoperative radiation ther-
apy [24]. This study was approved by the Committee on Hu-
man Research, University of California, San Francisco, Insti-
tutional Review Board.
Table 1: Patient characteristics and treatment details.
Variables Number
Number of patients 17
Median age (range), years 37 (8–86)
Female : male 8 : 9
Primary tumor location
Upper distal extremity 4
Upper proximal extremity 1
Lower distal extremity 3
Lower proximal extremity 9
Histology
Synovial sarcoma 6
Malignant fibrous histiocytoma 4
Alveolar rhabdomyosarcoma 2
Ewing sarcoma 2
Angiomyxoma 1
Angiosarcoma 1
Leiomyosarcoma 1
Stage (AJCC)
I 1
II 6
III 7
IV 3
EBRT, yes : no 13 : 4
Chemotherapy, yes : no 10 : 7
Surgical margins,∗ positive : negative 6 : 11
Disease status at time of IORT
Primary 16
Recurrent 1
Abbreviations: AJCC = American Joint Committee on Cancer. IORT =
intraoperative radiation therapy. EBRT = external beam radiation therapy.
∗A positive surgical margin was defined as a margin less than 1mm.
METHODS
Descriptive statistics were used to characterize these patients
with extremity sarcomas. A single group of 17 patients was
analyzed, and therefore no statistical comparisons of subsets
were performed. Between 1995 and 2001, 61 patients total
were treated with radiation for soft-tissue sarcomas of the ex-
tremities at our institution. The Kaplan-Meier product limit
method was used to estimate the probabilities of local con-
trol, DFS, and OS. Survival was measured from the date of
IORT treatment until the date of death or date of last con-
tact, if the patient was still alive. DFS was measured from the
date of IORT treatment until the date of failure or death or
date of last contact if the patient was last known to be disease
free. Local failure was defined as documented disease within
the radiation field or in the primary site, and regional fail-
ure was defined as disease recurrence directly adjacent to the
original site of disease or in adjacent lymph node groups.
RESULTS
Patient characteristics are summarized in Table 1. High-
grade lesions were noted in all stage II patients, while the
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Table 2: Patient outcome and follow-up.
Age Histology Location Presenting
stage
Failure IORT Site of
EBRT
Surgical
margins
Site of first Status FU
(months)Pt at of of in IORT dose progression at last
Dx primary primary field (Gy) after IORT FU
1 86 Malignant fibrous histiocytoma Buttock III Yes 12.5 Buttock − Buttock Dead 3
2 68 Malignant fibrous histiocytoma Thigh III No 12 Thigh − Acetabulum AWD 23
3 18 Synovial sarcoma Knee II No 15 Knee − Lungs AWD 15
4 39 Synovial sarcoma, recurrent Thigh IV No 15 Thigh − Lungs AWD 17
5 9 Alveolar rhabdomyosarcoma Calf III No 12 None − RP LN AWD 53
6 54 Angiosarcoma Thigh II No 15 Thigh + Lungs AWD 24
7 9 Ewing sarcoma Prox add IV No 12.5 Prox add + Lungs Dead 5
8 18 Ewing sarcoma Buttock IV No 12.5 Buttock + Lungs Dead 41
9 8 Monomorphic synovial sarcoma Forearm II No 12.5 Forearm + None NED 39
10 76 Malignant fibrous histiocytoma Groin III No 15 Groin/add − None NED 15
11 59 Malignant fibrous histiocytoma Forearm III No 12.5 Forearm + None NED 32
12 31 Angiomyxoma Thigh I No 15 None − None NED 37
13 20 Alveolar rhabdomyosarcoma Forearm III No 12.5 Forearm − None NED 17
14 21 Synovial sarcoma Shoulder II No 12.5 None − None NED 11
15 46 Synovial sarcoma Hand III No 12.5 Hand + None NED 34
16 37 Synovial sarcoma Popl fossa II No 12.5 Popl fossa − None NED 25
17 38 Leiomyosarcoma Groin II No 12.5 None − None Dead 23
Abbreviations: Pt = patient number; Dx = diagnosis; IORT = intraoperative radiation therapy; EBRT = external beam radiation therapy; FU = follow-up;
prox = proximal; add = adductor; popl = popliteal; RP = retroperitoneal; LN = lymph node; AWD = alive with disease; NED = no evidence of disease.
Note: Patients 1–2 failed locoregionally and patients 3–8 failed distantly.
single stage I patient had a low-grade lesion. Six stage III pa-
tients and one stage IV patient had high-grade lesions. No
grade was noted on pathology reports of one stage III patient
and two stage IV patients. All patients had GTRs, but 8 pa-
tients had previous attempts at resections. Following GTRs,
6 patients had positive surgical margins. Ten of 17 patients
received chemotherapy as part of their initial treatment. Al-
though it is our institutional policy to administer neoadju-
vant chemotherapy for most high-grade sarcomas in adults
(usually a doxorubicin- or ifosfamide-based regimen), the
remaining patients did not receive chemotherapy due to ei-
ther low-grade histology, advanced age, or poor Karnofsky
performance status.
IORT was administered at the time of original presenta-
tion in 16 patients and at the time of tumor recurrence in 1
patient. Thirteen of 17 patients received postoperative exter-
nal beam radiation therapy, with a median dose of 50.3Gy
(range 43.2–61.2 Gy) and a median number of 26 fractions
(range 20–33 fractions). Treatment was completed within
a median time of 76 days (range 62–118 days) from date
of IORT. Although the intent of the study was to adminis-
ter IORT as a boost to EBRT, four patients did not receive
EBRT; one patient received brachytherapy, two patients de-
clined EBRT, and one patient died of unrelated causes be-
fore receiving EBRT. The patient who received brachyther-
apy in addition to IORT had an unusual dumbbell-shaped
tumor and his treatment differed somewhat from the stan-
dard approach at our institution. The superficial portion of
the tumor was completely resected and received IORT; the
deep portion of the tumor proved unresectable at the time of
surgery and was therefore treated with brachytherapy.
Patient follow-up and clinical outcomes are summarized
in Table 2. Patients 1–8 experienced disease recurrence. Pa-
tient 1 failed within the IORT field, but died of metastatic
disease 3 months after surgery and IORT. Patient 2 failed ad-
jacent to the IORT field and is currently alive with disease
(AWD). Patients 3–8 failed at distant sites, with five patients
developing lungmetastases and one patient having retroperi-
toneal lymph nodes involvement. None of the 6 patients with
positive surgical margins had a local recurrence. Three pa-
tients presented with metastatic disease at the time of diag-
nosis (patients 4, 7, and 8). Patient 4 is AWD 17 months after
diagnosis, and patients 7 and 8 died of metastatic disease, 5
and 41 months after diagnosis, respectively, both with con-
trol of local disease sites.
Median follow-up for all patients was 23 months (range
3–53 months), with median follow-up for surviving patients
of 24 months (range 11–53 months). Median OS was 41
months but only 1 patient has been followed beyond the me-
dian time indicating that this estimate may reflect censoring
(Figure 1). Eight patients are alive with no evidence of dis-
ease (NED). One patient died of unrelated causes prior to
initiation of EBRT, while still NED. Median DFS was 23.4
months, resulting from 2 locoregional failures, 6 distant fail-
ures, and 1 death without recurrence (Figure 2). Two of 17
patients failed locoregionally at 2 and 11 months after IORT
(Figure 3). The median has not been reached for locore-
gional control, but locoregional control remains at 86% as
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Figure 1: Overall survival. Kaplan-Meier probability estimates.
Four of the 17 patients died.
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Figure 2: Disease-free survival. Kaplan-Meier probability esti-
mates. Two patients failed locoregionally, 6 patients failed distantly,
and 1 patient died without recurrence.
of 11 months after IORT with the longest failure-free obser-
vation being 44 months. Thirty-six month estimates for lo-
coregional control, DFS, and OS, were 86%, 50%, and 78%,
respectively.
Of the 17 patients, five were 18 years of age or younger
at diagnosis. Three of the five pediatric patients had posi-
tive surgical margins following GTRs. None of the pediatric
patients recurred locally. Patient 5 developed retroperitoneal
lymph node metastases and is currently AWD. Of patients 3,
7, and 8 who developed lungmetastases, two have died of dis-
ease and one is AWD. Patient 9, who presented with localized
synovial sarcoma of the forearm, is alive, without evidence of
disease, 39 months after resection with IORT.
IORT was extremely well tolerated in our cohort. Al-
though follow-upwas not long enough to assess late toxicities
associated with IORT, there were no acute toxicities noted.
Of the 13 patients who received subsequent EBRT, six expe-
rienced mild to moderate erythema, one experienced pain,
one blistering, and three patients experienced desquamation.
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Figure 3: Locoregional control. Two of the 17 patients failed locore-
gionally.
DISCUSSION
STSs are characterized by high local recurrence rates follow-
ing surgical excision alone. While the addition of radiation
therapy has successfully improved local control, multimodal-
ity therapy for extremity sarcomas has sustained local con-
trol rates while limiting the need for amputations and mor-
bid surgical procedures. The benefits of radiation therapy
for STSs have been documented in retrospective as well as
prospective, randomized trials [13, 24]. However, delivering
adequate doses of EBRT to extremity lesions can present par-
ticular challenges.
Complications including wound breakdown, skin graft
failure, and flap necrosis occur in approximately 17% of pa-
tients receiving postoperative EBRT and 35% of patients re-
ceiving preoperative EBRT [24–26]. In addition, extremities
are particularly susceptible to long-term sequelae of fibrosis
and edema resulting from EBRT administered in the preop-
erative or postoperative setting [24]. We therefore sought to
enhance the benefits of EBRT, while reducing associated tox-
icities by utilizing an IORT boost for patients with extremity
STSs.
In the treatment of sarcomas, IORT has generally been
used for tumors arising in the abdomen and pelvis. In a
prospective trial of retroperitoneal sarcomas, 35 patients
were randomized between 50–55Gy of EBRT alone and 20
Gy IORT plus 35–40Gy EBRT. Although initial analyses
demonstrated less toxicity in the IORT arm without im-
provement in DFS or OS [27], an updated analysis revealed
a significant reduction in locoregional recurrences in the
group receiving IORT [28]. This group also had a lower in-
cidence of disabling enteritis, although peripheral neuropa-
thy was more common in the IORT group than among con-
trols receiving high-dose EBRT without IORT. Amore recent
phase I trial of patients with localized retroperitoneal sarco-
mas demonstrated that IORT was feasible and was success-
fully administered [22].
Few studies address local control, tissue tolerance, and
effectiveness of IORT in the treatment of extremity STSs.
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Azinovic et al reported a study of 45 patients with extremity
STSs treated with IORT [29]. They reported 5-year local con-
trol rates of 88% in patients with negative surgical margins
and 57% in patients with positive surgical margins. Five pa-
tients developed neuropathies following treatment. Dubois
et al published a series of 31 patients with STSs, of which 18
patients had extremity STSs treated with IORT [30]. They
reported 4 local failures among the 31 patients but no local
failures in patients with extremity or trunk STSs.
Van Kampen et al treated 68 extremity STS patients with
IORT and reported a 5-year OS of 70% and local control rate
of 88% [31]. Analyzing a subset of 58 patients for late se-
quelae using the LENT-SOMA scoring system for soft-tissue
fibrosis, they noted that 4 patients had Grade 1-, 2 patients
had Grade 2-, 5 patients had Grade 3-, and 1 patient had
Grade 4-fibrosis. Lehnert et al reported a series of 251 pa-
tients with soft-tissue sarcomas; 131 patients had extremity
STSs, of which 55 received IORT [32]. Five-year OS and local
control rates were 78% and 83%, respectively, with a surgical
complication rate of 25%. Although treatment assignment
to IORT was nonrandom, it is interesting to note that among
patients who did not receive IORT, the 5-year OS rate was
57% and the 5-year local control rate was 68%, reflecting a
trend toward decreased morbidity andmortality with the use
of IORT.
Given these preliminary, yet promising experiences of
IORT in the treatment of STSs, we sought to explore our in-
stitutional experience using IORT as a component of mul-
timodality therapy for extremity STSs. Of these patients, 17
had extremity STSs that were treated with IORT and the lo-
coregional control was 86%, a figure comparable to prior
published results. There were no locoregional recurrences
in the 6 patients with positive surgical margins. Previous
studies have shown a lower local regional control rate in
patients with positive surgical margins [1, 29], but our re-
sults suggest that IORT as a boost could represent an im-
provement in the management of these patients. In addi-
tion, EBRT administered to the extremities poses particu-
lar challenges with significant risks of fibrosis, edema, and
compromised function. IORT was well tolerated in our co-
hort with no acute toxicities, but follow-up was not long
enough to comment on late toxicities such as neuropathy
or fibrosis. Thirteen patients experienced various degrees of
dermal toxicities following EBRT, none of unexpected sever-
ity.
Although we present encouraging results, the report is
limited by the retrospective nature of the study. It includes a
small number of patients, diverse histologies, various stages
of presentation, and multiple treatment techniques. How-
ever, given these hopeful results, we anticipate a future
prospective study that will address these limitations. In such
a future study, we hope to demonstrate the utility of IORT
as a boost to EBRT and a means of providing excellent lo-
cal control with limited acute toxicity. It is our institution’s
policy to use IORT as a boost to EBRT for all patients with
soft-tissue sarcomas of the extremity in whom proximity to
critical structures such as neurovascular bundles precludes
complete resection with adequate, negative margins.
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